| Cas No.: | 1056636-06-6 |
| Chemical Name: | Momelotinib sulfate |
| Synonyms: | Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, sulfate (1:2);CYT387 sulfate salt;N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide, sulfuric acid;CS-0765;CYT 387 sulfate;CYT-387 sulfate;CYT387,H2SO4salt;momelotinib sulfate;N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide sulfate (1:2);CYT387 2H2SO4 salt;CYT 387 sulfate (1:2);CYT387 (sulfate salt);Momelotinib sulfate |
| SMILES: | O=C(NCC#N)C(C=C1)=CC=C1C2=NC(NC(C=C3)=CC=C3N4CCOCC4)=NC=C2.O=S(O)(O)=O.O=S(O)(O)=O |
| Formula: | C23H22N6O2.2[H2O4S] |
| M.Wt: | 610.61674 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | A potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM; shows significantly less activity against other kinases, including JAK3 (IC50=155 nM); inhibits JAK2V617F (JH1-JH2) withIC50 of 11 nM; inhibits growth of Ba/F3-JAK2V617F and HEL cells (IC50=1500 nM) or Ba/F3-MPLW515L cells (IC50=200 nM). Bone CancerPhase 3 Clinical |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
